<DOC>
	<DOC>NCT00041496</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).</brief_summary>
	<brief_title>Prevention Of Recurrence Of Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Symptomatic persistent atrial fibrillation requiring DC cardioversion. Duration of AF &gt;48 hrs. &lt;6 months Concomitant Class I and/or III antiarrhythmic drugs. Amiodarone treatment within 3 months of the study. Other inclusion or exclusion criteria to be determined by the physician and study sponsor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>symptomatic atrial fibrillation</keyword>
	<keyword>persistent atrial fibrillation</keyword>
</DOC>